![]() |
市场调查报告书
商品编码
1661294
全球多癌症早期检测市场:按检测类型、技术、检体类型、最终用户和地区进行分析和预测(2024-2034 年)Multi-Cancer Early Detection Market - A Global and Regional Analysis: Focus on Test Type, Technology, Sample Type, End User, and Region - Forecast, 2024-2034 |
全球多癌症早期检测市场规模预计将从 2023 年的 9.359 亿美元激增至 2034 年的 51.535 亿美元,预测期内的复合年增长率为 16.30%。
市场正在经历显着的成长,主要原因是全球癌症发生率上升、早期诊断需求增加以及液态切片和基因组技术的进步。此外,精准医疗投资的增加、血液筛检测试的日益普及以及预防性医疗保健的推动也促进了市场的成长。
主要市场统计数据 | |
---|---|
预测期 | 2024-2034 |
2024 年评估 | 11.383亿美元 |
2034 年预测 | 51.535亿美元 |
复合年增长率 | 16.3% |
全球多癌症早期检测市场正在经历显着增长,这归因于人们越来越意识到早期发现癌症可以带来更高的生存机会和更好的治疗,同时主要市场参与企业之间日益增多的合作和战略伙伴关係正在加速多癌症早期检测的采用。这个市场受益于私人公司与学术和临床研究机构之间的密切合作。像这样的合作有助于弥合科学研究和实际应用之间的差距。公司通常提供资金、技术和商业化专业知识,而研究机构则提供科学知识、测试能力和患者资料。
从技术角度来看,次世代定序仪(NGS) 领域占据市场主导地位:
基于技术,NGS 领域预计将在 2023 年占据最大份额,预测期内复合年增长率为 17.33%,预计到 2034 年将达到 34.554 亿美元。 NGS 技术正在迅速发展,因为它提供了前所未有的能力来识别与各种癌症类型相关的基因突变、表观遗传学变化和其他生物标记。 NGS 能够从简单血液检体中对循环 DNA(ctDNA)和其他分子特征进行全面分析,从而实现同时对多种癌症进行非侵入性、准确的早期检测。它的高通量、扩充性以及检测罕见基因突变的能力使其成为多种癌症早期检测的有力工具。随着技术不断发展,灵敏度和资料分析能力不断提高,NGS 很可能在癌症筛检和个人化医疗的转变中发挥关键作用。
根据检体类型,血液学领域占据市场主导地位:
根据检体类型,血液学部分预计将在 2023 年占据最大份额,预测期内复合年增长率为 16.86%,预计到 2034 年将达到 45.866 亿美元。血液是用于早期检测多种癌症的常用检体类型,因为它具有微创、易于采集且能提供全面的生物资讯。血液中含有循环肿瘤 DNA(ctDNA)、循环性肿瘤细胞(CTC)、蛋白质和其他生物标记物,即使在早期阶段也可以指示癌症的存在。这些生物标记可能反映与各种癌症相关的基因突变、表观遗传学变化和其他分子变化。因此,血液检体类型是早期多种癌症检测的首选。
本报告调查了全球多癌症早期检测市场,并总结了主要趋势、影响市场的因素分析、法律制度、技术发展和专利趋势、案例研究、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。
市场区隔
细分一:依技术
细分 2:依检体类型
细分 3:按最终用户
细分 4:按地区
Introduction of Multi-Cancer Early Detection
The global multi-cancer early detection market, initially valued at $935.9 million in 2023, is set to witness substantial growth, projected to surge to $5,153.5 million by 2034, marking a remarkable compound annual growth rate (CAGR) of 16.30% over the period from 2024 to 2034. The market has been experiencing significant growth, primarily fuelled by the rising global cancer burden, increasing demand for early diagnosis, and advancements in liquid biopsy and genomic technologies. Moreover, growing investments in precision medicine, expanding adoption of blood-based screening tests, and the push for preventive healthcare also contribute to market growth.
Market Introduction
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2024 - 2034 |
2024 Evaluation | $1,138.3 Million |
2034 Forecast | $5,153.5 Million |
CAGR | 16.3% |
The global multi-cancer early detection market has been experiencing significant growth, fueled by raising awareness among the population about early detection of cancer leading to higher survival chances and better treatment, along with growing collaborations and strategic partnerships among key market players, which are accelerating the adoption of multi-cancer early detection. The multi-cancer early detection market is benefiting from strong collaboration between private companies and academic or clinical research institutes. These collaborations help bridge the gap between scientific research and real-world applications. Companies often provide the funding, technology, and commercialization expertise, while research institutes contribute their scientific knowledge, testing capabilities, and patient data. For instance, in October 2023, HCA Healthcare, Inc., Sarah Cannon Cancer Institute, and GRAIL, Inc. announced a strategic collaboration to advance comprehensive cancer care through early detection. Therefore, the introduction of advanced services, collaboration, and partnerships contribute to the rapid development, validation, and adoption of multi-cancer early detection, which holds the potential to revolutionize cancer diagnosis, improve patient outcomes, and reduce healthcare costs globally.
Industrial Impact
The multi-cancer early detection market has significantly influenced the healthcare landscape, driven by key players such as GRAIL, Inc., Burning Rock Biotech Limited, Exact Sciences Corporation, and Freenome Holding, Inc. These companies are at the forefront, providing cutting-edge platforms for multi-cancer early detection.
Moreover, the market has been further shaped by strategic collaborations, mergers, and R&D investments, which enable companies to expand their global presence and introduce innovative solutions. With the increasing focus on understanding tissue architecture and disease mechanisms, the competitive landscape of the multi-cancer early detection market is dynamic, with innovation and customer-centric approaches driving differentiation and growth.
Market Segmentation for Multi-Cancer Early Detection Market:
Segmentation 1: by Technology
Next-Generation Sequencing (NGS) Segment to Dominate the Multi-Cancer Early Detection Market (by Technology)
Based on technology, the global multi-cancer early detection market was led by the next-generation sequencing (NGS) segment, which accounted for the largest share in 2023 and is expected to reach $3,455.4 million by 2034, registering a CAGR of 17.33% during the forecast period 2024-2034. NGS technology is rapidly advancing in the multi-cancer early detection market, offering unprecedented capabilities for identifying genetic mutations, epigenetic alterations, and other biomarkers associated with various cancer types. NGS enables comprehensive analysis of circulating DNA (ctDNA) and other molecular signatures from a simple blood sample, simultaneously facilitating non-invasive, accurate, and early detection of multiple cancers. Its high throughput, scalability, and ability to detect rare genetic variants make it a powerful tool in the early detection of multi-cancers. As technology continues to evolve, with improvements in sensitivity and data analysis, NGS is set to play a critical role in transforming cancer screening and personalized medicine.
Segmentation 2: by Sample Type
Blood Segment to Dominate the Multi-Cancer Early Detection Market (by Sample Type)
Based on sample type, the global multi-cancer early detection market was led by the blood segment, which accounted for the largest share in 2023 and is expected to reach $4,586.6 million by 2034, registering a CAGR of 16.86% during the forecast period 2024-2034. Blood is commonly used as a sample type for multi-cancer early detection due to its minimally invasive nature, ease of collection, and ability to provide comprehensive biological information. It contains circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), proteins, and other biomarkers that can indicate the presence of cancer, even at early stages. These biomarkers can reflect genetic mutations, epigenetic alterations, and other molecular changes associated with various cancers. Therefore, blood sample type is mostly preferred for early multi-cancer detection.
Segmentation 3: by End User
Hospital Segment to Dominate the Multi-Cancer Early Detection Market (by End User)
Based on end user, hospitals accounted for the largest share in 2023 and are expected to reach $3,865.1 million by 2034, registering a CAGR of 16.60% during the forecast period 2024-2034. The expansion of this segment is driven by the growing demand for hospitals that provide comprehensive services in a single location. A significant benefit of hospitals offering multi-cancer diagnostics is their ability to deliver test results promptly, even in emergencies. Continuous advancements in hospital laboratories are crucial to addressing the changing needs of patients, prompting many hospitals to broaden their diagnostic and treatment offerings.
Segmentation 4: by Region
In 2023, Europe region dominated the global multi-cancer early detection market, however, the Asia-Pacific region is expected to register the highest CAGR of 17.79% during the forecast period 2024-2034. The Europe multi-cancer early detection market is driven by increasing awareness of cancer prevention, rapid advancements in diagnostic technologies, and rising healthcare investments, which are key factors driving the market growth. Government-funded screening programs targeting multi-cancers have played a pivotal role in promoting the adoption of innovative diagnostic solutions. Additionally, the integration of cutting-edge technology, including next-generation sequencing, continues to improve detection accuracy and effectiveness, making early diagnosis more accessible and reliable.
Recent Developments in the Multi-Cancer Early Detection Market
Demand - Drivers, Challenges, and Opportunities
Market Drivers:
Increasing Incidence of Cancer Leading to Increased Demand for Early Detection: The increasing incidence of various solid tumors, including breast, lung, and colorectal cancers, serves as a primary driver for the growth of the multi-cancer early detection market globally. According to data published by GLOBOCAN, approximately 19.98 million cancer cases were reported in 2022, with projections estimating this number to rise to 24.1 by 2030. This alarming increase in cancer cases is anticipated to accelerate demand for advanced diagnostic tools as healthcare providers seek effective strategies for early detection and personalized treatment options. Early detection of cancer plays a critical role in improving survival rates and reducing the complexity of treatments. Many types of cancer, when detected in the early stages, are treatable and manageable, with higher chances of complete recovery. Additionally, early diagnosis improves survival and enhances patients' quality of life by minimizing the intensity of treatment required. Thus, the increasing incidence of cancer is expected to accelerate the demand for early cancer detection.
Market Challenges:
High Cost of Multi-Cancer Early Detection Tests: The high costs associated with multi-cancer early detection tests continue to restrain the growth of the multi-cancer early detection market, making these innovative tools inaccessible to many. Multi-cancer early detection tests provide broader cancer detection; hence, they come at a higher cost than traditional single-cancer tests. Moreover, limited insurance reimbursement for such tests further compounds the issue. For instance, most insurance providers in the U.S. do not yet cover MCED tests, leaving patients to pay out-of-pocket. This high financial burden restricts the accessibility of these technologies to affluent populations and limits their integration into public health programs. As a result, while these technologies show promise in detecting multiple cancers at early stages, their high price points hinder large-scale adoption, particularly in economically constrained healthcare systems.
Market Opportunities:
Integration of Artificial Intelligence in Multi-Cancer Early Detection: The integration of artificial intelligence (AI) into cancer screening has revolutionized early detection methods, significantly boosting the multi-cancer early detection market. These innovations play a key role in improving diagnostic process accuracy, speed, and cost-effectiveness, enabling better outcomes and transforming cancer care. Moreover, AI and data analytics are being leveraged to combine multiple diagnostic modalities, such as blood tests, imaging, and genetic analysis, creating a comprehensive multi-cancer early detection system.
How can this report add value to an organization?
Product/Innovation Strategy: The global multi-cancer early detection market has been extensively segmented based on various categories, such as technology, sample type, end user, and region.
Growth/Marketing Strategy: Mergers, acquisitions, and product launches accounted for the maximum number of key developments.
Competitive Strategy: The global multi-cancer early detection market has numerous established players with product portfolios. Key players in the global multi-cancer early detection market analyzed and profiled in the study involve established players offering products for multi-cancer early detection.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
Primary Research:
The primary sources involve industry experts in multi-cancer early detection, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Secondary Research
Open Sources
The key data points taken from the secondary sources include:
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts, who have analyzed company coverage, product portfolio, and market penetration.
Some prominent names established in this market are: